Cargando…

PROCURE European consensus on breast cancer multigene signatures in early breast cancer management

Breast cancer multigene signatures (BCMS) have changed how patients with early-stage breast cancer (eBC) are managed, as they provide prognostic information and can be used to select patients who may avoid adjuvant chemotherapy. Clinical guidelines make recommendations on the use of BCMS; however, l...

Descripción completa

Detalles Bibliográficos
Autores principales:	Curigliano, Giuseppe, Cardoso, Fatima, Gnant, Michael, Harbeck, Nadia, King, Judy, Laenkholm, Anne-Vibeke, Penault-Llorca, Frédérique, Prat, Aleix
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9951144/ https://www.ncbi.nlm.nih.gov/pubmed/36828834 http://dx.doi.org/10.1038/s41523-023-00510-9

Ejemplares similares

Customizing early breast cancer therapies – The 2021 St. Gallen International Breast Cancer Consensus Conference()
por: Gnant, Michael, et al.
Publicado: (2022)

St. Gallen/Vienna 2021: A Brief Summary of the Consensus Discussion on Customizing Therapies for Women with Early Breast Cancer
por: Thomssen, Christoph, et al.
Publicado: (2021)

Why is appropriate healthcare inaccessible for many European breast cancer patients? – The EBCC 12 manifesto
por: Cardoso, Fatima, et al.
Publicado: (2021)

Circulating proteins as predictive and prognostic biomarkers in breast cancer
por: Veyssière, Hugo, et al.
Publicado: (2022)

Customizing local and systemic therapies for women with early breast cancer: the St. Gallen International Consensus Guidelines for treatment of early breast cancer 2021
por: Burstein, H.J., et al.
Publicado: (2021)

Comparison of different commercial kits for HER2 testing in breast cancer: looking for the accurate cutoff for amplification
por: Cayre, Anne, et al.
Publicado: (2007)

aHIF but not HIF-1α transcript is a poor prognostic marker in human breast cancer
por: Cayre, Anne, et al.
Publicado: (2003)

5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5)
por: Cardoso, F., et al.
Publicado: (2020)

Breaking down the Contradictory Roles of Histone Deacetylase SIRT1 in Human Breast Cancer
por: Rifaï, Khaldoun, et al.
Publicado: (2018)

Multigene tests for breast cancer: the physician’s perspective
por: Cognetti, Francesco, et al.
Publicado: (2021)

3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)
por: Cardoso, F, et al.
Publicado: (2017)

3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)
por: Cardoso, F., et al.
Publicado: (2017)

Co-targeting EGFR and mTOR with gefitinib and everolimus in triple-negative breast cancer cells
por: El Guerrab, Abderrahim, et al.
Publicado: (2020)

Assessment of Ki67 in Breast Cancer: Updated Recommendations From the International Ki67 in Breast Cancer Working Group
por: Nielsen, Torsten O, et al.
Publicado: (2020)

The PROMISe to increase precision in adjuvant therapy for early breast cancer: To “Type” or to “Print”?
por: Cardoso, Fatima, et al.
Publicado: (2018)

Deconstructing the molecular portraits of breast cancer
por: Prat, Aleix, et al.
Publicado: (2010)

PARP Inhibitors: A Major Therapeutic Option in Endocrine-Receptor Positive Breast Cancers
por: Collet, Laetitia, et al.
Publicado: (2022)

The Epigenetic Landscape of Promoter Genome-wide Analysis in Breast Cancer
por: Karsli-Ceppioglu, Seher, et al.
Publicado: (2017)

The multigene signature MammaPrint impacts on multidisciplinary team decisions in ER(+), HER2(−) early breast cancer
por: Exner, R, et al.
Publicado: (2014)

Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013
por: Goldhirsch, A., et al.
Publicado: (2013)

Dissecting the biological heterogeneity of HER2-positive breast cancer
por: Schettini, Francesco, et al.
Publicado: (2021)

Anti-EGFR monoclonal antibodies and EGFR tyrosine kinase inhibitors as combination therapy for triple-negative breast cancer
por: Guerrab, Abderrahim El, et al.
Publicado: (2016)

Refining patient selection for breast cancer immunotherapy: beyond PD-L1
por: Kossai, M., et al.
Publicado: (2021)

Current challenges and unmet needs in treating patients with human epidermal growth factor receptor 2-positive advanced breast cancer
por: Aapro, Matti, et al.
Publicado: (2022)

Intrinsic molecular subtypes of HER2+ breast cancer
por: Prat, Aleix, et al.
Publicado: (2017)

Multigene prognostic tests in breast cancer: past, present, future
por: Győrffy, Balázs, et al.
Publicado: (2015)

The Role of Multigene Assays in Addressing Treatment Heterogeneity for Breast Cancer
por: Aapro, Matti
Publicado: (2017)

Chromogenic in situ hybridisation for the assessment of HER2 status in breast cancer: an international validation ring study
por: van de Vijver, Marc, et al.
Publicado: (2007)

Dual SIRT1 expression patterns strongly suggests its bivalent role in human breast cancer
por: Rifaï, Khaldoun, et al.
Publicado: (2017)

Advanced Breast Cancer: AGO Recommendations 2022 – Focus on ABC6 Consensus
por: Untch, Michael, et al.
Publicado: (2022)

Cellular Expression of Cyclooxygenase, Aromatase, Adipokines, Inflammation and Cell Proliferation Markers in Breast Cancer Specimen
por: Basu, Samar, et al.
Publicado: (2015)

SIRT1-dependent epigenetic regulation of H3 and H4 histone acetylation in human breast cancer
por: Rifaï, Khaldoun, et al.
Publicado: (2018)

ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2)(†)
por: Cardoso, F., et al.
Publicado: (2014)

BRCA1 Induces Major Energetic Metabolism Reprogramming in Breast Cancer Cells
por: Privat, Maud, et al.
Publicado: (2014)

Physical basis of the ‘magnification rule’ for standardized Immunohistochemical scoring of HER2 in breast and gastric cancer
por: Scheel, Andreas H., et al.
Publicado: (2018)

Triple-Negative Breast Cancer Risk Genes Identified by Multigene Hereditary Cancer Panel Testing
por: Shimelis, Hermela, et al.
Publicado: (2018)

An Update on Breast Cancer Multigene Prognostic Tests—Emergent Clinical Biomarkers
por: Vieira, André Filipe, et al.
Publicado: (2018)

Clinical outcomes based on multigene profiling in metastatic breast cancer patients
por: Basho, Reva K., et al.
Publicado: (2016)

Tumor microenvironment-related multigene prognostic prediction model for breast cancer
por: Hong, Kai, et al.
Publicado: (2022)

Cytokeratin on Frozen Sections of Sentinel Node May Spare Breast Cancer Patients Secondary Axillary Surgery
por: Stovgaard, Elisabeth Specht, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_112bd2bae3ii6u8r6113csd3sn